Study of the economic efficiency of the combined method of Octreotide-depo + dexamethasone therapy in the treatment of patients with castration-resistant prostate cancer

Abstract

Prostate cancer (PC) is one of the major health problems of the male population. The most difficult is the treatment of metastatic castration-resistant prostate cancer (mCRPC), which is the main cause of mortality from PC. In the course of treatment of PC, it inevitably becomes refractory to castration, characterized by the growth of PSA and clinical signs of progression. Octreotidedepo, a representative of the synthetic analogue of somatostatin of prolonged action, has a therapeutic effect in patients with CRPC with a positive total response in the form of a decrease or stabilization of the PSA level, the drug has a favorable safety profile and is easily tolerated by patients. The economic benefit of Octreotide-depo is estimated in the article. Cost-effectiveness analysis has shown its high clinical and economic efficiency. After the establishment of CRPC, first of all, the preparation Oсtreotide-depo will allow to postpone the start of chemotherapy with docetaxel or hormonal therapy of the 2nd line by 7–8 months and save up to 17% of funds in the first year of treatment.

Keywords

• prostate cancer
• castration-resistant prostate cancer
• analogues of somatostatin
• octreotide
• abiraterone
• docetaxel
• median of relapse-free survival
• clinical efficiency
• pharmacoeconomics
• cost analysis
• cost-benefit analysis